Table 1.
The development of anti-CD47 therapies.
| Name | Target | Progress | Company |
|---|---|---|---|
| Hu5F9-G4 | CD47 | Phase I/II clinical | Stanford University Forty Seven |
| TI-061 | CD47 | Phase I/II clinical | Arch Oncology |
| TTI-622 | SIRPα | Phase I clinical | Trillum Therapeutics |
| TTI-621 | SIRPα | Phase I clinical | Trillum Therapeutics |
| SRF231 | CD47 | Phase I clinical | Surface Oncology |
| SHR-1603 | CD47 | Phase I clinical | Hengrui |
| OSE-172 | SIRPα | Phase I clinical | Boehringer Ingelheim OSE Immunotherapeutics |
| NI-1701 | CD47 CD19 | Phase I clinical | Novimmune TG Therapeutics |
| IBI188 | CD47 | Phase I clinical | Innovent Biologics |
| CC-95251 | SIRPα | Phase I clinical | Celgene |
| CC-90002 | CD47 | Phase I clinical | Celgene Inibrx |
| AO-176 | CD47 | Phase I clinical | Arch Oncology |
| ALX148 | SIRPα | Phase I clinical | ALX Oncology |
| IMM01 | SIRPα | Applying for a clinical trial | ImmuneOnco Biopharma |
| TJC4 | CD47 | Applying for a clinical trial | I-MAB Biopharma |
| TJC4-CK | CD47 | Preclinical trial | I-MAB Biopharma |
| SY102 | CD47 | Preclinical trial | Saiyuan |
| SL-172154 | CD40L SIRPα | Preclinical trial | Shattuck Labs |
| PSTx-23 | CD47 | Preclinical trial | Paradigm Shift Therapeutics |
| PDL1/CD47BsAb | PD-L1 CD47 | Preclinical trial | Hanmi Pharmaceuticals |
| NI-1801 | CD47 MSLN | Preclinical trial | Novimmune |
| MBT-001 | CD47 | Preclinical trial | Morphiex |
| LYN00301 | CD47 | Preclinical trial | LynkCell |
| IMM2504 | PDL1 CD47 VEGF | Preclinical trial | ImmuneOnco Biopharma |
| IMM2502 | PDL1 CD47 | Preclinical trial | ImmuneOnco Biopharma |
| IMM03 | CD20 CD47 | Preclinical trial | ImmuneOnco Biopharma |
| IMM02 | SIRPα VEGFR1 | Preclinical trial | ImmuneOnco Biopharma |
| IMC-002 | CD47 | Preclinical trial | ImmuneOncia Therapeutics |
| IBI322 | PDL1 CD47 | Preclinical trial | Innovent Biologics |
| HMBD-004B | CD47 | Preclinical trial | Hummingbird Bioscience |
| HMBD-004A | CD47 CD33 | Preclinical trial | Hummingbird Bioscience |
| HLX24 | CD47 | Preclinical trial | Henlius |
| FSI-189 | SIRPα | Preclinical trial | Forty Seven |
| DSP107 | SIRPα 4-1BBL | Preclinical trial | KAHR medical |
| CTX-5861 | SIRPα | Preclinical trial | Compass Therapeutics |
| BAT6004 | CD47 | Preclinical trial | Bio-Thera |
| AUR-105 | CD47 | Preclinical trial | Aurigene |
| AUR-104 | CD47 | Preclinical trial | Aurigene |
| ANTI-CD47 MAB | CD47 | Preclinical trial | Biocad |
| ABP-500 | CD47 TWEAKR | Preclinical trial | Abpro |
| ABP-160 | PDL1-CD47 | Preclinical trial | Abpro |
| BH-29xx | PD1-CD47 | Preclinical trial | Beijing Hanmi |